Acumen Pharmaceuticals Files 8-K on Financials

Ticker: ABOS · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1576885

Acumen Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyAcumen Pharmaceuticals, INC. (ABOS)
Form Type8-K
Filed DateMar 19, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001, $306 million
Sentimentneutral

Sentiment: neutral

Topics: financial-results, operations, sec-filing

Related Tickers: ACUM

TL;DR

ACUM filed an 8-K detailing financial results and operations.

AI Summary

Acumen Pharmaceuticals, Inc. filed an 8-K on March 19, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 427 Park St., Charlottesville, Virginia.

Why It Matters

This 8-K filing provides crucial updates on Acumen Pharmaceuticals' financial performance and operational status, which can influence investor decisions.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting financial results and does not indicate any unusual or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Acumen Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to report on Acumen Pharmaceuticals, Inc.'s results of operations and financial condition, along with Regulation FD disclosures and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on March 19, 2024.

Where are Acumen Pharmaceuticals, Inc.'s principal executive offices located?

Acumen Pharmaceuticals, Inc.'s principal executive offices are located at 427 Park St., Charlottesville, Virginia.

What is the SEC file number for Acumen Pharmaceuticals, Inc.?

The SEC file number for Acumen Pharmaceuticals, Inc. is 001-40551.

What is the Standard Industrial Classification code for Acumen Pharmaceuticals, Inc.?

The Standard Industrial Classification code for Acumen Pharmaceuticals, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-03-19 08:05:09

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 19, 2024, Acumen Pharmaceuticals, Inc. (the "Company") posted an updated corporate presentation (the "Corporate Presentation") to its website at https://investors.acumenpharm.com/news-events/presentations, which the Company may use from time to time in communications or conferences. The Corporate Presentation was updated to reflect that, as of December 31, 2023, the Company's cash, cash equivalents and marketable securities balance was approximately $306 million (which amount includes proceeds received to date under the Company's Loan and Security Agreement with K2 HealthVentures LLC), based upon which the Company projects that its cash, cash equivalents and marketable securities will be sufficient to support the Company's operations into the first half of 2027. A copy of the Corporate Presentation containing this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report"). The cash, cash equivalents and marketable securities information above is based on preliminary unaudited information and management estimates for the year ended December 31, 2023, is not a comprehensive statement of the Company's financial results as of and for the fiscal year ended December 31, 2023, and is subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, this preliminary estimate.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The information in Item 2.02 of this Current Report is incorporated into this Item 7.01 by reference. The Corporate Presentation was also updated to reflect the Company's anticipation that it will amend its ALTITUDE-AD Phase 2/3 study protocol to become a Phase 2 standalone study. The information contained in Items 2.02 and 7.01 of this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d). Exhibits Exhibit No. Description 99.1 Corporate Presentation, dated March 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acumen Pharmaceuticals, Inc. Dated: March 19, 2024 By: /s/ Derek Meisner Derek Meisner Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing